Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GOP Players In Health Debate: McCain To HELP; Enzi Adds Finance To Resume

Executive Summary

In the face of substantially higher Democratic congressional majorities, two Republican senators have ensured their place in the debate over health care reform and providing Americans with access to safe medicines

You may also be interested in...

Senate Follow-On Biologics Bill Still Stuck In Evergreen Forest

Despite moving a bill out of committee last session, the Senate is still wrangling over the issue of whether modifications of existing products should get full exclusivity.

Globalization Bill Creates Fees For Generic Pre-approval Inspections

A system for assessing fees for generic drug applicants to pay for pre-approval inspections is included in the 1FDA Globalization Act introduced in the House Jan. 28

Senate Committee Clears Stimulus Bill With “Comparative Clinical Effectiveness” Funding

Amended bill language and the bill report make clear that research should assess which medical treatments “work best,” rather than which are most cost-effective.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts